Two big phar­ma ex­ecs share the same chal­lenges, but com­pen­sa­tion? They’re not even close

Big Phar­ma ex­ecs may share big con­cerns like the bat­tle over drug pric­ing, big patent cliffs and the dilem­ma over pipeline pro­duc­tiv­i­ty, but they don’t get paid the same.

A brief glimpse of 2 new SEC fil­ings from Ab­b­Vie $AB­BV and Sanofi $SNY un­der­score the chasm of wealth that can sep­a­rate peers in this lofty realm. 

Ab­b­Vie CEO Richard Gon­za­lez bagged a pack­age worth a to­tal of $21.3 mil­lion for 2018, down slight­ly from $22.6 mil­lion from the year be­fore. R&D chief Michael Sev­eri­no took home com­pen­sa­tion worth $8.6 mil­lion. And that’s more than Sanofi CEO Olivi­er Brandi­court made.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER